HALVING TIME OF BCR-ABL1 IN CHRONIC MYELOID LEUKEMIA, IS IT BETTER THAN A 90 DAY VALUE? A MULTICENTRE STUDY FROM INDIA

Krishnakumar Rathnam1; Arun Seshachalam2; Shashidhar Karpurmath3; Manjunath Nandennavar4; Kalaiselvi Selvaraj5; Neelesh Reddy5; Srinievi Roopa5; Amula Sathishkumar5; S.G. Raman6; Janardhinakani Murugesan6; Baswant Mallipati7; Krishnaprasad Bhat7; Krishna Reddy8; Channappa N. Patil9; Karthik Uduppa10

1Meenakshi Mission Hospital & Research Centre, Madurai, 2GVN Institute of Oncology, Trichy, 3Vydehi Institute of Medical Sciences, Begaluru, 4AllIMS, Nagpur, 5Columbia Asia Hospital, Begaluru, 6Madras Cancer Care Foundation, Chennai, 7Mangalore Institute of Oncology, Mangalore, 8Manipal Hospital, Vijayawada, 9Apollo Hospital, Bengaluru, 10Manipal Hospital, Manipal, India

Background – Day90 Bcr-ABL1 levels is widely followed in predicting the molecular response in CML. Rate of decline in Bcr-ABL1 is being studied as a predictor of response though not uniformly accepted. There is paucity of evidence to predict the accuracy of rate of decline in the Indian context.

Aim: To test the accuracy of rate of decline of Bcr-ABL1 in predicting the molecular response compared to standard on day90 values.

Settings: The retrospective cohort study based on available patient case records from selected cancer centers in south India.

Methods and Materials: Among CML patients diagnosed between January 2013 and December 2018, serial bcr-ABL1 levels were estimated on the following days: 30, 45, 90, six months and one year. Data on patient demographics, risk stratification as assessed by SOKAL and EUTOS were extracted in mobile based data capture tool.

Statistical Analysis: Halving time based on log reduction was compared with day90 Bcr-ABL1 values using receiver operating characteristic curve against major and complete molecular response at 6 months and one year as standards. Accuracy was determined based on Area under Curve. Cutoff for halving time was chosen based on tradeoff between sensitivity and specificity.

Results: Rate of decline had more predictive accuracy compared to day90 bcr-ABL1 values (AUC: rate of decline: 0.83, day90:0.80). Halving time of less than 20 days identified 95% of the patients who achieved MMR at 12 months whereas it was 80% for optimal day 90 BCR-ABL1 response.

Conclusion- Halving time of Bcr-ABL1 appears promising in prediction of outcome in CML.